Short answer
Design Therapeutics, Inc. (DSGN) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Design Therapeutics reported financial results for Q2 and six months ended June 30, 2026.
Design Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Design Therapeutics reported financial results for Q2 and six months ended June 30, 2026
- Results detailed in Exhibit 99.1, the company’s accompanying earnings press release
- Disclosure furnished under Item 2.02, limiting Exchange Act Section 18 liability and incorporation into other filings
Item EX-99.1 · Exhibit EX-99.1
- Q2 net loss $20.2M, or $0.32 per share, with R&D spending of $16.4M
- Cash and securities $207.4M at June 30, down from $219.8M at December 31
- RESTORE-FA advancing at 1 mpk, with 12-week data expected in Q1 2027
- DT-216P2 trial modifications make endogenous FXN protein change the primary efficacy endpoint
- DT-818 dosing began in DM1, while DT-168 FECD data shifted to 2027 due to eye-dropper supply delays
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Design Therapeutics, Inc. 8-K filings
Get the next DSGN 8-K as it lands
Follow DSGN for push alerts, or ask the research agent what this filing means.